摘要
原发性肝癌(PHC)的早期诊断比较困难,迄今,甲胎蛋白(AFP)仍是诊断PHC唯一最特异性的肿瘤标志物。但由于部分早期及进展期肝细胞癌不分泌AFP,因此约有30％～40％的肝癌病人AFP表现假阴性结果。Deugnier等自1980年以来先后报道PHC病人血清α-L岩藻糖苷酶(AFU)的活性明显升高,提出AFU可作为诊断PHC的新标志物。近几年来,国内也讨论热烈。为此,我们对广东地区223例病人的血清AFU、AFP分别进行检测,以探讨AFU对PHC,尤对AFP阴性的PHC病人的临床诊断价值。现报道如下。 对象及方法 一、观察对象:1992～1993年本院住院部各病区收治的223例病人,其中(1)原发性肝癌50例,男性43例,女性7例,年龄31～73岁,平均年龄50.2岁。
Of 223 patients, 50 were primary hepatocellu-lar carcinoma (PHC), 13 secondary metastatic liver cancer, 53 various liver diseases, 40 gastrointestinal tumor and 67 other diseases, the serumα-L -Fucosidase (AFU) and α-fetoprotein (AFP) levels were checked in 50 cares as controls. The result showed that AFU level was significantly, higher in PHC (667.33± 231.57) than that in the controls (230 ± 96.6) and in patients with other diseases (P<0.001).
When 450μmol/L·h was taken as the positine determining value, AFU Sensitivity and specificity were 86% and 82%, respectively. The diagnostic positivity was 61.5% in low AFP in PHC. The combination rate was 90.2%. Our data suggest that serum α - L - Fucosidase is a useful tumor marker for PHC. It can complement the deficiency of AFP, and may become a procedure of the eanly diagnosis for PHC.
出处
《广东医学》
CAS
CSCD
1994年第4期220-221,共2页
Guangdong Medical Journal
